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Saliva as major human body ﬂuid may act as an indicator of oral
disease status. Oral mucositis is a common and often treatment-
limiting side effect of radiotherapy for head and neck cancer
patients. In this dataset, we provide the complete proteome dataset
(raw and search ﬁles) of the patients at baseline of radiotherapy
treatment in patients undergoing radiotherapy analyzed by nano
liquid chromatography coupled to mass spectrometry (LC–MS/MS).
In the data set, 5323 tryptic peptides were identiﬁed which can be
assigned to 487 distinct proteins (Z2 peptides). The MS data have
been deposited to the ProteomeXchange (“ProteomeXchange provides
globally coordinated proteomics data submission and dissemination”
[1]) via the PRIDE partner repository with the dataset identiﬁer
PRIDE: PXD003230. The data are associated with the previously
published work, “Differences in the whole saliva baseline proteomevier Inc. This is an open access article under the CC BY license
/j.jprot.2015.04.030
wald, Interfaculty Institute for Genetics and Functional Genomics, Depart-
hn-Str. 15a, 17475 Greifswald, Germany.
Völker).










N. Jehmlich et al. / Data in Brief 8 (2016) 501–505502proﬁle associated with development of oral mucositis in head and neck
cancer patients undergoing radiotherapy” [2].
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Biology
ore speciﬁc sub-
ject areaClinical Proteomicsype of data Table
ow data was
acquiredData were recorded using nano-liquid chromatography coupled to an LTQ
Orbitrap Velos mass spectrometerata format 1) raw (Thermo instrument output ﬁles)
2) .msf (Proteome Discoverer output ﬁles)xperimental
factorsPatients received Intensity-modulated radiation (IMRT). Whole saliva was col-
lected from patients at least three days before the radiotherapy started.xperimental
features1) Whole saliva collection
2) Protein precipitation
3) Proteolytic digestion using trypsin
4) LC–MS/MS analysisata source
locationGreifswald, Mecklenburg – West Pomerania, Germanyata accessibility Data are within this article and deposited to the ProteomeXchange Consortium
via the PRIDE partner repository with the dataset identiﬁer PRIDE: PXD003230.Value of the data
 Protein signatures of whole saliva from head and neck cancer patients are useful to differentiate
between healthy and disease subjects screening for signatures of radiation associated oral
mucositis (OM).
 Proteomics revealed correlation of the abundance of 48 of the 488 proteins identiﬁed with the risk
of developing OM which allow further investigations towards biomarker assays.
 Whole saliva protein proﬁles at baseline of radiotherapy might allow identiﬁcation of patients
prone to adverse reactions.1. Data
In this dataset, we measured the whole saliva proteome of patients for differences related to the
development of oral mucositis. The data present here are (i) LC–MS/MS raw data and (ii) database
search ﬁles of 50 head and neck cancer patients.2. Experimental design, materials and methods
We collected unstimulated whole saliva of 50 patients before receiving radiotherapy. After
treatment, 41 out of 50 patients developed oral mucositis (grade III) during radiotherapy, of which 14
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1 x x Oropharynx IVa yes
2 x x Oropharynx IVa no
3 x x Hypopharynx IVa yes
4 x x Hypopharynx IVa yes
5 x x Larynx IVb yes
6 x x Hypopharynx IVa yes
7 x x Oropharynx III yes
8 x x Oropharynx IVa yes
9 x x Oropharynx IVa yes
11 x x Oropharynx IVb yes
12 x x Hypopharynx IVa yes
13 x x Oropharynx IVa no
14 x x Larynx 0 no
15 x x Larynx IVa yes
16 x x Hypopharynx IVa no
17 x x Larynx IVb yes
18 x x Hypopharynx IVa yes
19 x x Hypopharynx IVa no
20 x x Oropharynx IVa yes
21 x x Oropharynx IVa yes
22 x x Oropharynx IVa yes
23 x x Oropharynx IVa yes
24 x x Oropharynx IVa yes
25 x x Larynx IVa yes
26 x x Hypopharynx IVa yes
27 x x Oropharynx IVa yes
28 x x Oropharynx IVa no
29 x x oral cavity IVa yes
31 x x Oropharynx IVa yes
33 x x Oropharynx IVa yes
34 x x Larynx IVa yes
48 x x Nasopharynx II yes
49 x x Hypopharynx IVa yes
51 x x Hypopharynx IVb yes
52 x x Larynx IVa yes
53 x x oral cavity III yes
62 x x Oropharynx IVa yes
64 x x Hypopharynx IVa yes
65 x x Hypopharynx IVa yes
66 x x Oropharynx IVa yes
67 x x Oropharynx IVa yes
68 x x Oral cavity I yes
70 x x Hypopharynx IVa yes
71 x x Larynx IVa no
72 x x Oropharynx IVa yes
73 x x Oropharynx II yes
74 x x Maxillary antrum III yes
75 x x Oropharynx IVa no
77 x x Larynx IVb no
78 x x Oropharynx III yes
N. Jehmlich et al. / Data in Brief 8 (2016) 501–505 503patients even displayed an early oral mucositis (grade III) at low radiation dose of 30 Gy. Nine patients
did not develop OM (grade III). The whole set were prepared for LC–MS/MS analysis and the acquired
data are provided.
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The volume of whole saliva ranged from 0.2 to 1.7 mL (average 0.970.3 mL). To acquire this
proteome dataset, 0.5 mL aliquots of whole saliva proteins were precipitated using trichloroacetic
acid (TCA) at a ﬁnal concentration of 10% (v/v) and dithiothreitol (0.12% w/v) as described [3]. Brieﬂy,
protein pellets were resuspended in 8 M urea/ 2 M thiourea buffer. For MS-analysis, 4 mg of protein
lysate were reduced (2.5 mM DTT for 1 h at 60 °C) and alkylated (10 mM iodacetamide for 30 min at
37 °C). Proteolysis was performed overnight using trypsin (Promega, Madison, WI, USA). Tryptic
cleavage was stopped by adding 1% acetic acid followed by desalting and puriﬁcation using ZipTip-
mC18 tips (Millipore, Billerica, MA, USA).4. Mass spectrometric analysis
The 50 patient samples were measured in a randomized design. Proteolytically cleaved peptides
were separated prior to MS analyses by reverse phase nano HPLC on a 15 cm Acclaim PepMap100-
column (C18, 3 mm, 100 Å) using an EASY-nLC Proxeon system (Thermo Scientiﬁc, Waltham, MA, USA)
at a constant ﬂow rate of 300 nL/min. The LC separation was achieved using a linear gradient of buffer
B from 5% up to 25% within 63 min with 0.1% acetic acid, 2% acetonitrile in water (solvent A) and 0.1%
acetic acid in 100% acetonitrile (solvent B). Peptides were measured using an LTQ Orbitrap Velos
instrument (Thermo Scientiﬁc) equipped with a nano electrospray ion source operated with PicoTip
Emitters (New Objective, Woburn, MA, USA). After a ﬁrst survey scan with a resolution of 30,000, the
MS/MS data were measured for the top 20 mass peaks in the linear ion trap at collision induced
energy (CID) of 35%. The raw MS-data were processed using the Reﬁner MS v7.5 module (Genedata,
Basel, Switzerland). Peak lists were searched against a human FASTA-formatted database containing
20,268 unique entries (human_uniprot_swissprot_2011_10.fasta) using an in-house Mascot server
v2.3.2 (Matrix Science, London, GB). Database searches were performed with carbamidomethyl on
cysteine as ﬁxed modiﬁcation and oxidation on methionine as variable modiﬁcation. Enzyme spe-
ciﬁcity was selected to trypsin with up to two missed cleavages allowed using 10 ppm peptide ion
tolerance and 0.6 Da MS/MS tolerances. Only ranked 1 peptide hits and a Mascot ion score 423 were
considered as identiﬁed (Table 1).Acknowledgments
The Greifswald part of the project was performed within the framework of the research project
Greifswald Approach to Individualized Medicine (GANI_MED). The GANI_MED consortium was fun-
ded by the Federal Ministry of Education and Research and the Ministry of Cultural Affairs of the
Federal State of Mecklenburg – West Pomerania (03IS2061A). We are grateful to Jette Anklam for
technical assistance.Transparency document. Supplementary material
Transparency document associated with this article can be found in the online version at http://dx.
doi.org/10.1016/j.dib.2016.05.053.References
[1] J.A. Vizcaino, E.W. Deutsch, R. Wang, A. Csordas, F. Reisinger, D. Rios, J.A. Dianes, Z. Sun, T. Farrah, N. Bandeira, P.A. Binz,
I. Xenarios, M. Eisenacher, G. Mayer, L. Gatto, A. Campos, R.J. Chalkley, H.J. Kraus, J.P. Albar, S. Martinez-Bartolome,
R. Apweiler, G.S. Omenn, L. Martens, A.R. Jones, H. Hermjakob, ProteomeXchange provides globally coordinated proteomics
data submission and dissemination, Nat. Biotechnol. 32 (3) (2014) 223–226.
N. Jehmlich et al. / Data in Brief 8 (2016) 501–505 505[2] N. Jehmlich, P. Stegmaier, C. Golatowski, M.G. Salazar, C. Rischke, M. Henke, U. Volker, Differences in the whole saliva
baseline proteome proﬁle associated with development of oral mucositis in head and neck cancer patients undergoing
radiotherapy, J. Proteom. 125 (2015) 98–103.
[3] N. Jehmlich, K.H. Dinh, M. Gesell-Salazar, E. Hammer, L. Steil, V.M. Dhople, C. Schurmann, B. Holtfreter, T. Kocher, U. Volker,
Quantitative analysis of the intra- and inter-subject variability of the whole salivary proteome, J. Periodontal Res. 48 (3)
(2013) 392–403.
